How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra